of0
Export
 
CDE Detailed Report
This report contains detailed information about the selected CDEs.
Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report.
Disease: Parkinson's Disease
Sub-Domain: Quality of Life/Patient Reported Outcomes
CRF: Parkinson's Disease Quality of Life Scale (PDQUALIF)
Item count: 33 (33 distinct CDEs)
CDE ID
CDE Name
Variable Name
Definition / Description
Question Text
Permissible Value
Description
Data Type
Instructions
References
Population
Classification (e.g., Core)
Version #
Version Date
Aliases for Variable Name
CRF Module / Guideline
© or TM
Sub-Domain
Domain
Previous Title
Size
Input Restrictions
Min Value
Max Value
Measurement Type
LOINC ID
SNOMED
caDSR ID
CDISC ID
C17361
Parkinson's Disease Quality of Life (PDQUALIF) - lightheaded scale
PDQUALIFLghtHdScale
Rating scale for lightheaded symptom caused by changing positions (lying to standing, or sitting to standing) as part of Parkinson's Disease Quality of Life (PDQUALIF) form
Changing positions causes me to become lightheaded (lying to standing, or sitting to standing)
Never;Rarely;Sometimes;Occasionally;Always;
Never;Rarely;Sometimes;Occasionally;Always;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q1
 
Single Pre-Defined Value Selected
       
C17362
Parkinson's Disease Quality of Life (PDQUALIF) - trouble balance scale
PDQUALIFTroubBalScale
Rating scale for trouble keeping balance while walking as part of Parkinson's Disease Quality of Life (PDQUALIF) form
When walking, I have trouble keeping my balance
Never;Rarely;Sometimes;Occasionally;Always;
Never;Rarely;Sometimes;Occasionally;Always;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q2
 
Single Pre-Defined Value Selected
       
C17363
Parkinson's Disease Quality of Life (PDQUALIF) - difficult swallowing scale
PDQUALIFDiffcltSwallScale
Rating scale for difficulty swallowing while eating or drinking liquids as part of Parkinson's Disease Quality of Life (PDQUALIF) form
When eating or drinking liquids, I have difficulty swallowing
Never;Rarely;Sometimes;Frequently;Always;
Never;Rarely;Sometimes;Frequently;Always;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q3
 
Single Pre-Defined Value Selected
       
C17364
Parkinson's Disease Quality of Life (PDQUALIF) - communication ability scale
PDQUALIFCommunAbScale
Rating scale for ability of communication with people affected by illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form
My Parkinson’s symptoms affect my ability to communicate with people
Never;Rarely;Sometimes;Frequently;Always;
Never;Rarely;Sometimes;Frequently;Always;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q4
 
Single Pre-Defined Value Selected
       
C17365
Parkinson's Disease Quality of Life (PDQUALIF) - night wakeup bathroom scale
PDQUALIFNghtWakeBRScale
Rating scale for waking up at night due to the need to go to the bathroom as part of Parkinson's Disease Quality of Life (PDQUALIF) form
The need to go to the bathroom wakes me in the night
Never;Rarely;Sometimes;Frequently;Always;
Never;Rarely;Sometimes;Frequently;Always;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q5
 
Single Pre-Defined Value Selected
       
C17366
Parkinson's Disease Quality of Life (PDQUALIF) - affection ability scale
PDQUALIFAffectnAbScale
Rating scale for ability to show affection in intimate or sexual ways affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form
My Parkinson’s symptoms affect my ability to show affection in intimate or sexual ways
Never;Rarely;Sometimes;Frequently;Always;
Never;Rarely;Sometimes;Frequently;Always;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q6
 
Single Pre-Defined Value Selected
       
C17367
Parkinson's Disease Quality of Life (PDQUALIF) - aching limb scale
PDQUALIFAcheLimbScale
Rating Scale for having aching/burning/coldness/numbness in the hand/feet as part of Parkinson's Disease Quality of Life (PDQUALIF) form
I have aching/burning/coldness/numbness in my hand/feet
Never;Rarely;Sometimes;Frequently;Always;
Never;Rarely;Sometimes;Frequently;Always;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q7
 
Single Pre-Defined Value Selected
       
C17368
Parkinson's Disease Quality of Life (PDQUALIF) - difficulty bladder control scale
PDQUALIFDiffcltBladContScale
Rating scale for difficulty with bladder control (frequency, urgency, inability) as part of Parkinson's Disease Quality of Life (PDQUALIF) form
I have difficulty with bladder control (frequency, urgency, inability)
Never;Rarely;Sometimes;Frequently;Always;
Never;Rarely;Sometimes;Frequently;Always;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q8
 
Single Pre-Defined Value Selected
       
C17369
Parkinson's Disease Quality of Life (PDQUALIF) - constipation scale
PDQUALIFConstipScale
Rating scale for constipation problem as part of Parkinson's Disease Quality of Life (PDQUALIF) form
Constipation is a problem
Never;Rarely;Sometimes;Frequently;Always;
Never;Rarely;Sometimes;Frequently;Always;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q9
 
Single Pre-Defined Value Selected
       
C17370
Parkinson's Disease Quality of Life (PDQUALIF) - trouble fall asleep scale
PDQUALIFTroubFallAslpScale
Rating scale for trouble falling asleep, or waking early due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form
My Parkinson’s symptoms cause me to have trouble falling asleep, or waking early
Never;Rarely;Sometimes;Frequently;Always;
Never;Rarely;Sometimes;Frequently;Always;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q10
 
Single Pre-Defined Value Selected
       
C17371
Parkinson's Disease Quality of Life (PDQUALIF) - trouble stay asleep scale
PDQUALIFTroubStayAslpScale
Rating scale for trouble staying asleep as part of Parkinson's Disease Quality of Life (PDQUALIF) form
I have trouble staying asleep
Never;Rarely;Sometimes;Frequently;Always;
Never;Rarely;Sometimes;Frequently;Always;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q11
 
Single Pre-Defined Value Selected
       
C17372
Parkinson's Disease Quality of Life (PDQUALIF) - positive outlook scale
PDQUALIFPositvOutlkScale
Rating scale for maintaining a positive outlook due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form
My Parkinson's symptoms make it hard to maintain a positive outlook
Never;Rarely;Sometimes;Frequently;Always;
Never;Rarely;Sometimes;Frequently;Always;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q12
 
Single Pre-Defined Value Selected
       
C17373
Parkinson's Disease Quality of Life (PDQUALIF) - feel burden scale
PDQUALIFFeelBurdScale
Rating scale for feeling a burden to other people due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form
My Parkinson's symptoms cause me to feel like a burden to other people
Never;Rarely;Sometimes;Frequently;Always;
Never;Rarely;Sometimes;Frequently;Always;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q13
 
Single Pre-Defined Value Selected
       
C17374
Parkinson's Disease Quality of Life (PDQUALIF) - affected social life scale
PDQUALIFSocLfAffctedScale
Rating scale for affected social life by Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form
My Parkinson's symptoms have affected my social life
Never;Rarely;Sometimes;Frequently;Always;
Never;Rarely;Sometimes;Frequently;Always;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q14
 
Single Pre-Defined Value Selected
       
C17375
Parkinson's Disease Quality of Life (PDQUALIF) - worry future scale
PDQUALIFWorryFutScale
Rating scale for worrying about what the future has in store as part of Parkinson's Disease Quality of Life (PDQUALIF) form
I worry about what the future has in store
Never;Rarely;Sometimes;Frequently;Always;
Never;Rarely;Sometimes;Frequently;Always;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q15
 
Single Pre-Defined Value Selected
       
C17376
Parkinson's Disease Quality of Life (PDQUALIF) - difficulty ask help scale
PDQUALIFAskHelpScale
Rating scale for feeling difficult to ask others for help as part of Parkinson's Disease Quality of Life (PDQUALIF) form
Asking others for help is difficult for me
Never;Rarely;Sometimes;Frequently;Always;
Never;Rarely;Sometimes;Frequently;Always;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q16
 
Single Pre-Defined Value Selected
       
C17377
Parkinson's Disease Quality of Life (PDQUALIF) - independent important scale
PDQUALIFIndepImportScale
Rating scale for feeling important to maintain independence as part of Parkinson's Disease Quality of Life (PDQUALIF) form
Maintaining my independence is important to me
Never;Rarely;Sometimes;Frequently;Always;
Never;Rarely;Sometimes;Frequently;Always;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q17
 
Single Pre-Defined Value Selected
       
C17378
Parkinson's Disease Quality of Life (PDQUALIF) - difficulty adjust change scale
PDQUALIFDiffcltAdjtChngScale
Rating scale for feeling difficult to adjust to the changes which have taken place in the body as part of Parkinson's Disease Quality of Life (PDQUALIF) form
It has been difficult to adjust to the changes which have taken place in my body
Very;Moderately;Somewhat;Slightly;Not at all;
Very;Moderately;Somewhat;Slightly;Not at all;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q18
 
Single Pre-Defined Value Selected
       
C17379
Parkinson's Disease Quality of Life (PDQUALIF) - social life not affected scale
PDQUALIFSocLfNotAffctedScale
Rating scale for feeling that the social life has not been affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form
My Parkinson’s symptoms have not affected my social life
Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree;
Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q19
 
Single Pre-Defined Value Selected
       
C17380
Parkinson's Disease Quality of Life (PDQUALIF) - travel important scale
PDQUALIFTravelImportScale
Rating scale for feeling that travel remains an important part of leisure activities as part of Parkinson's Disease Quality of Life (PDQUALIF) form
Travel remains an important part of my leisure activities
Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree;
Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q20
 
Single Pre-Defined Value Selected
       
C17381
Parkinson's Disease Quality of Life (PDQUALIF) - family role affected scale
PDQUALIFFamRoleAffctedScale
Rating scale for family role and relationship affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form
My Parkinson’s symptoms have affected my family role and relationship
Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree;
Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q21
 
Single Pre-Defined Value Selected
       
C17382
Parkinson's Disease Quality of Life (PDQUALIF) - away from social scale
PDQUALIFAwyFrmSocScale
Rating scale for staying away from social gatherings due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form
My Parkinson’s symptoms cause me to stay away from social gatherings
Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree;
Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q22
 
Single Pre-Defined Value Selected
       
C17383
Parkinson's Disease Quality of Life (PDQUALIF) - family friends view change scale
PDQUALIFFamFridViewChngScale
Rating scale for feeing that your spouse/children/friends' view of you has changed because of your illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form
My spouse/children/friends’ view of me has changed because of my illness
Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree;
Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q23
 
Single Pre-Defined Value Selected
       
C17384
Parkinson's Disease Quality of Life (PDQUALIF) - less sexually desirable scale
PDQUALIFLesSexDesirblScale
Rating scale for feeling of less sexually desirable because of the illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form
I feel I am less sexually desirable because of my illness
Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree;
Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q24
 
Single Pre-Defined Value Selected
       
C17385
Parkinson's Disease Quality of Life (PDQUALIF) - hygiene independence 7 days scale
PDQUALIFHygienIndep7DaysScale
Rating scale for personal hygiene (bathing, hair care, make up, shaving, or toileting) independence in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form
In the past 7 days, in my personal hygiene (bathing, hair care, make up, shaving, or toileting) I have been independent
Everyday;5-6 Days;3-4 Days;1-2 days;Never;
Everyday;5-6 Days;3-4 Days;1-2 days;Never;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q25
 
Single Pre-Defined Value Selected
       
C17386
Parkinson's Disease Quality of Life (PDQUALIF) - food preparation eating independent 7 days scale
PDQUALIFFoodPrepEatIndep7DScl
Rating scale for preparing and eating independently in the past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form
In the past 7 days, in food preparation or eating I am independent
Everyday;5-6 Days;3-4 Days;1-2 days;Never;
Everyday;5-6 Days;3-4 Days;1-2 days;Never;
Alphanumeric
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.
Adult
Supplemental–Highly Recommended
3.0
7/18/2013
Aliases for variable name not defined
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Quality of Life/Patient Reported Outcomes
Outcomes and End Points
PDQUALIF Q26
 
Single Pre-Defined Value Selected
       
07-20-2019
Page 1 of 2